A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NCT05257083)

🧪 Interventions in This Study

• Daratumumab (DRUG)
• Bortezomib (DRUG)
• Lenalidomide (DRUG)
• Dexamethasone (DRUG)
• Cilta-cel (DRUG)
• Cyclophosphamide (DRUG)
• Fludarabine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (106 Sites)

Showing the first 25 of 106 sites.

• University of Arkansas — Little Rock, Arkansas
• City of Hope — Duarte, California
• UC San Diego Health Moores Cancer Center — San Diego, California
• University of California San Francisco (UCSF) — San Francisco, California
• Stanford University — Stanford, California
• Moffit Cancer Center — Tampa, Florida
• Emory University Hospital — Atlanta, Georgia
• University of Chicago — Chicago, Illinois
• University of Iowa — Iowa City, Iowa
• University Of Maryland Medical Center — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Boston Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Karmanos Cancer Center — Detroit, Michigan
• Mount Sinai Medical Center — New York, New York
• Memorial Sloan-Kettering Cancer Center — New York, New York
• University of Rochester — Rochester, New York
• Montefiore M-E Center — The Bronx, New York
• Levine Cancer Institute — Charlotte, North Carolina
• Duke University Medical Center — Durham, North Carolina
• Cleveland Clinic — Cleveland, Ohio
• The Ohio State University — Columbus, Ohio
• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
• University of Texas Southwestern Medical Center — Dallas, Texas
• University of Virginia — Charlottesville, Virginia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.